Home to the second-largest pharmaceutical market in the world, Japan has poised itself as one of the most lucrative biotech hubs in Asia and worldwide. Over recent years, the Japanese biologics market has opened its doors to both foreign companies entering the Japanese market and companies investing abroad. Japan’s biopharma sector has had a keen eye on alliance opportunities in markets beyond its borders and although the nature of its sector is a cautious one, its move towards transparency and international collaboration provides bountiful opportunities that both the domestic and international players stand to benefit from.
The key drivers driving the growth of the biologics industry in Japan are the formation of numerous bio-clusters that house world-class universities with cutting-edge technologies and know-how, excellence in the implementation of automation technology, huge amounts of financial support for orphan drugs, tax breaks, and subsidies for new entrants in the market, the government’s push for the creation of technologies and services, and development of the supporting infrastructure. Factors hindering the growth of the biopharmaceutical industry mainly are from the bioprocessing side including high manufacturing complexities expensive purification processes and other challenges across the bioprocessing value chain. Meanwhile trials and roll outs for COVID vaccines and antivirals will position Japan at the forefront of crucial life-saving initiatives.Agenda of the BMK 2022 is built around success stories from korea’s biopharmas as well as the technical expertise from international biopharmas and big pharmas, presentations on the latest manufacturing technologies such as single-use and end-to-end continuous processing for biologics, today’s challenges and opportunities in biomanufacturing, advances in upstream process development, cost-optimization strategies in downstream processing, analytical characterization strategies, advanced bioprocessing technique and antibody production, fill & finish innovation to streamline the operations amongst other crucial themes.
Japanese Biologicals Competing in the Global Market
Driving Investment in Japanese Biologicals
Gene Therapy Process Development
Drug Pricing and Logistics
AAV Vector Manufacturing
Downstream Bioprocessing and Fill & Finish and Packaging
CAR-T/ NK Cell Manufacturing
A world leader in the design and manufacture of high-performance temperature-controlled packaging systems for the transport of pharmaceutical products, EMBALL’ISO is now an expert of turnkey Reuse, Reverse Logistics and Rental solutions.
EMBALL’ISO’s worldwide presence across 4 continents, with 8 production sites (Brazil, China, France, Germany, India, Singapore, UK and the US), 14 Services Centre and collection points in more than 80 countries helps you reuse isothermal packaging while saving time and money.
We supply systems capable of carrying a single vial to airfreight pallet shippers available flat packed or fully assembled in new and innovative Logistics Business models.
EMBALL’ISO delivers quality everywhere, just like you.
Peli BioThermal is the first cold chain packaging solutions provider to make available a broad and comprehensive portfolio of patented and award-winning single-use and reusable thermal protection packaging solutions for the safe transport of pharmaceuticals, clinical trials, diagnostics, tissue, vaccines and blood supplies for the life science industry.
Collaboration with our clients is the first step to ensure we provide a solution that is built around the unique and very specific needs of your temperature-sensitive payloads. Our global services network provides consultation, support, engineering and deployment for your cold chain distribution challenges wherever they exist.
Peli BioThermal designs products to ensure our customers valuable payloads are kept in perfect condition, irrespective of external temperatures and conditions. They are designed to be strong and robust, to survive the rigors of international transport. With environmental issues in mind, we ensure that our design team specify the correct materials and consider ‘end of life’ recycling for all of our ranges, whether they are single use or reusable packaging systems.
Marken is a wholly owned subsidiary of UPS and is a critical part of UPS Healthcare. With Polar Speed and Marken included, the UPS Healthcare division staffs 128 locations with 5,500 employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 59 locations worldwide, while maintaining the leading position for Direct-to-Patient and Home Healthcare services, biological sample shipments and biological kit production.
Marken’s dedicated 2,000 staff members manage 135,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 11,500+ home healthcare visits. Additional services such as cell and gene supply chain services, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.